sb 203580 has been researched along with malonic acid in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (malonic acid) | Trials (malonic acid) | Recent Studies (post-2010) (malonic acid) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 905 | 1 | 231 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aguirre, N; Barros-Miñones, L; Goñi-Allo, B; Hervías, I; Orejana, L; Puerta, E; Suquía, V | 1 |
1 other study(ies) available for sb 203580 and malonic acid
| Article | Year |
|---|---|
Modulation of the ASK1-MKK3/6-p38/MAPK signalling pathway mediates sildenafil protection against chemical hypoxia caused by malonate.
Topics: Administration, Oral; Animals; Anthracenes; Apoptosis; Hypoxia, Brain; Imidazoles; Male; Malonates; MAP Kinase Signaling System; Neuroprotective Agents; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyridines; Rats; Rats, Wistar; Reactive Oxygen Species; Sildenafil Citrate; Sulfonamides | 2013 |